Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
‘I believe that beginning 2014 will see a change in the landscape’
I feel that the recent changes in the filling requirement for abbreviated new drug applications brought about by the FDA will have…
’Indian regulatory scenario is far from rosy at these times’
I have been a firm believer and a positive thinker on Indian pharma industry and its capabilities and strengths to scale the…
‘Let this be the tipping point, but in a way that is to the benefit of all…
A year ago the impending Drug Prices Control Order (DPCO) was a key topic for debate. One year down the line the new DPCO has been…
’Game cards need to be played with lot of concentration and long-term vision’
There is definitely a transformation seen in the Indian pharma industry. Indian pharma industry is a long term player in the…
Raise your game – Expand your horizons in the Indian OTC market
Sreedevi Yallamrazu, Sr Strategic Analyst, CubeX, provides a snapshot of the dynamics of the Indian OTC market and various…
Rising above Neglect
In January last year, 13 pharmaceutical companies alongwith the US, the UK and the UAE governments; Bill & Melinda Gates…
Jubilant Biosys files IND with US-based Endo Pharmaceuticals
IND relates to a novel molecule targetting prostate cancer
DoP extends excise duty exemption on formulations under DPCO 2013
No extension in the deadlines set for price revision
World’s pharma development manufacturing base moving to India: IBEF
Generics exports growth of nearly 30 per cent enabling greater research spend
Ranbaxy allocates site for greenfield manufacturing facility in Malaysia
Agreement signed with Kulim Hi Tech Park